Cargando…
Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
Eighty-five percent of multiple sclerosis cases begin with a discrete attack termed clinically isolated syndrome, but 37% of clinically isolated syndrome patients do not experience a relapse within 20 years of onset. Thus, the identification of biomarkers able to differentiate between individuals wh...
Autores principales: | Probert, Fay, Yeo, Tianrong, Zhou, Yifan, Sealey, Megan, Arora, Siddharth, Palace, Jacqueline, Claridge, Timothy D W, Hillenbrand, Rainer, Oechtering, Johanna, Leppert, David, Kuhle, Jens, Anthony, Daniel C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111065/ https://www.ncbi.nlm.nih.gov/pubmed/33997784 http://dx.doi.org/10.1093/braincomms/fcab084 |
Ejemplares similares
-
Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands
por: Probert, Fay, et al.
Publicado: (2022) -
Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands
por: Probert, Fay, et al.
Publicado: (2022) -
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
por: Yeo, Tianrong, et al.
Publicado: (2022) -
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
por: Yeo, Tianrong, et al.
Publicado: (2021) -
A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application
por: Yeo, Tianrong, et al.
Publicado: (2020)